[go: up one dir, main page]

MX2022006990A - Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico. - Google Patents

Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.

Info

Publication number
MX2022006990A
MX2022006990A MX2022006990A MX2022006990A MX2022006990A MX 2022006990 A MX2022006990 A MX 2022006990A MX 2022006990 A MX2022006990 A MX 2022006990A MX 2022006990 A MX2022006990 A MX 2022006990A MX 2022006990 A MX2022006990 A MX 2022006990A
Authority
MX
Mexico
Prior art keywords
crystalline form
annulene
benzo
carboxylic acid
acid derivative
Prior art date
Application number
MX2022006990A
Other languages
English (en)
Inventor
Pascal Billot
Benoît Robert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2022006990A publication Critical patent/MX2022006990A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción se refiere a un compuesto de fórmula (1) como un anhidrato que está en una forma cristalina 2, caracterizado por tener un difractograma de rayos X de polvo que muestra picos expresados como ángulos de grado 2-Theta en aproximadamente 9.5; 11.8; 14.1; 14.6; 17.7 y 18.5 y una forma sólida de los mismos. La presente divulgación también se relaciona con los procesos para su preparación, así como con un medicamento y una composición farmacéutica que lo contiene. La presente descripción se refiere además a la Forma 2 cristalina de anhidrato del compuesto de fórmula (1) para su uso como medicamento y más particularmente en el tratamiento del cáncer.
MX2022006990A 2019-12-09 2020-12-08 Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico. MX2022006990A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306599 2019-12-09
PCT/EP2020/085011 WO2021116074A1 (en) 2019-12-09 2020-12-08 Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative

Publications (1)

Publication Number Publication Date
MX2022006990A true MX2022006990A (es) 2022-07-13

Family

ID=69174249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006990A MX2022006990A (es) 2019-12-09 2020-12-08 Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.

Country Status (13)

Country Link
US (1) US20230028566A1 (es)
EP (1) EP4073036B1 (es)
JP (1) JP2023504912A (es)
KR (1) KR20220113695A (es)
CN (1) CN114761381B (es)
AU (1) AU2020399168A1 (es)
BR (1) BR112022009705A2 (es)
CA (1) CA3160897A1 (es)
CO (1) CO2022006929A2 (es)
IL (1) IL293252A (es)
MX (1) MX2022006990A (es)
TW (1) TW202138346A (es)
WO (1) WO2021116074A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI803692B (zh) 2018-09-07 2023-06-01 法商賽諾菲公司 用於製備6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸甲酯之方法
CA3160897A1 (en) * 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
WO2023287938A1 (en) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Solid state forms of amcenestrant
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3524600T3 (da) 2016-02-15 2022-02-07 Sanofi Sa Fremgangsmåder og mellemprodukter til fremstilling af hidtil ukendte substituerede 6,7-dihydro-5h-benzo[7]annulenforbindelser
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7571006B2 (ja) * 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
TWI803692B (zh) 2018-09-07 2023-06-01 法商賽諾菲公司 用於製備6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸甲酯之方法
CA3160897A1 (en) * 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative

Also Published As

Publication number Publication date
BR112022009705A2 (pt) 2022-08-09
TW202138346A (zh) 2021-10-16
CO2022006929A2 (es) 2022-08-19
EP4073036C0 (en) 2023-11-01
KR20220113695A (ko) 2022-08-16
AU2020399168A1 (en) 2022-07-28
IL293252A (en) 2022-07-01
WO2021116074A1 (en) 2021-06-17
CN114761381A (zh) 2022-07-15
EP4073036A1 (en) 2022-10-19
EP4073036B1 (en) 2023-11-01
US20230028566A1 (en) 2023-01-26
JP2023504912A (ja) 2023-02-07
CN114761381B (zh) 2025-03-14
CA3160897A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
ECSP22058816A (es) Compuestos tric?clicos sustituidos
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
CL2011001924A1 (es) Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6540003A2 (es) Inhibidor de bromodominio de benzodiazepina
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
CO6220963A2 (es) Cocristales y composiciones farmaceuticas que los comprenden
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
BR112015004523A2 (pt) compostos de tetraciclina
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
DOP2024000239A (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
MX2024010104A (es) Compuesto bicíclico condensado que contiene pirrolinona.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
AR127496A1 (es) Compuestos de cd73
AR050914A1 (es) Agonista receptor de vasopresina peptidico